Business Context and Reporting Period
This Form 8-K is a current report filed by Targacept, Inc. (not Gyre Therapeutics, Inc.) on August 18, 2006, regarding events occurring on August 16, 2006. The filing addresses changes to the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Resignation: Ann F. Hanham resigned from the Board of Directors on August 16, 2006.
- Election: G. Steven Burrill was elected as a Class III director to fill the vacancy created by Ms. Hanham's resignation.
- Term: Mr. Burrill's term continues until the third annual meeting of stockholders following the initial classification in April 2006.
- Committee Assignment: Mr. Burrill will serve as a member of the Audit Committee.
Management Commentary and Background
Mr. Burrill is the CEO of Burrill & Company LLC, a merchant bank he founded in 1994. He previously spent 27 years with Ernst & Young LLP, including 17 years as a partner. He had previously served on the Targacept Board from August 2000 to August 2005.
Key Facts for Investor Verification
- Confirm the identity of the registrant as Targacept, Inc., distinct from Gyre Therapeutics, Inc.
- Verify the effective date of the board changes (August 16, 2006).
- Note the return of G. Steven Burrill to the Board after a one-year absence.
- Recognize that no financial data or operational guidance is contained in this specific filing.